Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon Globocare Corp (ALBT) delivers innovative solutions at the intersection of biotechnology and healthcare services. This dedicated news hub provides investors and industry observers with essential updates on the company’s advancements in cell-based therapies, precision diagnostics, and healthcare facility management.
Access authoritative reports covering clinical milestones, financial disclosures, and strategic partnerships. Our curated collection includes press releases on therapeutic developments, regulatory updates, and operational expansions within ALBT’s dual business segments: real property management and medical consulting services.
Key areas of coverage include progress in early cancer detection systems, regenerative medicine research, and healthcare infrastructure developments. All content is verified for accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to ALBT’s latest announcements. Check regularly for updates reflecting the company’s role in advancing biotechnological innovation and patient care solutions.
Avalon GloboCare (NASDAQ: ALBT) has announced a definitive merger agreement with YOOV, a leading business AI automation solutions provider. The merged entity will operate as YOOV and trade under the ticker 'YOOV' on Nasdaq, pending approval.
YOOV demonstrated strong financial performance with unaudited revenue of $45.7 million and net income of $3.4 million for calendar year 2024, compared to $28.7 million revenue and $2.4 million net loss in 2023, representing 59.1% annual revenue growth.
Post-merger ownership structure will see YOOV shareholders holding approximately 97.5-97.8% of the combined company, while Avalon shareholders will retain 2.2-2.5%. The transaction is expected to close in Q3 2025, subject to stockholder approval. Phil Wong will serve as Chairman, CEO, and President of the combined company, with a seven-member board comprising five YOOV and two Avalon designees.
Avalon GloboCare (NASDAQ: ALBT) has received a Notice of Allowance from China's National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele The patent covers innovative CAR-T and CAR-NK cell technology, extending Avalon's intellectual property beyond the U.S. and PCT territories.
The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to minimize tumor escape risk. It also includes a localized cytokine induction system that enhances CAR cell effectiveness and activates anti-tumor immune responses specifically upon tumor engagement.
According to CEO David Jin, this platform technology aims to provide practical, cost-effective solutions for point-of-care cancer treatment, potentially improving accessibility and patient outcomes globally.
Avalon GloboCare (NASDAQ: ALBT), a precision diagnostics and laboratory services developer, has received notice from Nasdaq on November 19, 2024, confirming its regained compliance with the exchange's minimum bid price requirement under Rule 5550(a)(2). The company's CEO, David Jin, emphasized their commitment to shareholders and corporate governance, stating their continued focus on creating sustainable long-term value for both shareholders and stakeholders.
Avalon GloboCare (NASDAQ: ALBT) has launched the 'BrAce for Impact' affiliate marketing program for KetoAir™, an AI-enabled breathalyzer device for ketogenic health monitoring. The program, developed following demand from recent health conferences, offers affiliates discount codes and commissions on sales.
The initiative provides marketing materials and brand resources to affiliates, targeting metabolic coaches, podcasters, health authors, and influencers. KetoAir™, FDA-registered (No. 3026284320), measures breath acetone concentration using nano-sensor technology to assess ketosis status, with companion apps available on both Apple and Google platforms.
Avalon GloboCare (NASDAQ: ALBT) has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board to support the development of KetoAir™, a handheld breathalyzer for ketogenic health monitoring. Dr. Cavo, co-founder and CMO of Pounds Transformation, brings expertise in obesity medicine and bariatric care. KetoAir™ measures Breath Acetone Concentration (BrAce) as a biomarker for ketosis, offering a non-invasive alternative to blood and urine testing. The device aims to support weight management and conditions like diabetes by providing real-time feedback on ketosis levels.
Avalon GloboCare (NASDAQ: ALBT) has entered into a memorandum of understanding with Qi Diagnostics to explore co-developing a VOC nanosensor-based cannabis breathalyzer. The MOU grants Avalon a 120-day exclusivity period to negotiate a definitive agreement. If successful, the collaboration would focus on developing a prototype for detecting cannabis, leveraging Avalon's regulatory expertise and experience with clinical trials. The project aims to address point-of-care testing needs in law enforcement and workplace safety. However, there is no guarantee that a definitive agreement will be reached during the exclusivity period.
Avalon GloboCare (NASDAQ: ALBT) has announced a 1-for-15 reverse stock split effective October 28, 2024, as part of its strategy to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will reduce outstanding common shares from approximately 16.0 million to 1.1 million. The company will continue trading under the symbol 'ALBT' with a new CUSIP number 05344R302. The move is aimed at maintaining Nasdaq listing while the company continues focusing on its precision diagnostics and laboratory services business.
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced its sponsorship of the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, in Louisville, KY. The company will showcase its KetoAir™ breathalyzer device, designed to monitor ketosis through breath analysis. Conference attendees will have the opportunity to see live demonstrations and purchase the device along with related accessories on-site.
The KetoAir™ breathalyzer is a handheld device specifically engineered for ketogenic health management. It measures breath acetone concentration (BrAce) to assess ketosis status without invasive blood tests. The device is FDA-registered and accessible via both Apple App Store and Google Play Store. Avalon's subsidiary, Q&A Distribution , holds exclusive distributorship rights for KetoAir™ in North America, South America, EU, and UK.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% stake, will begin manufacturing and selling the GeeWhiz External Condom Catheter, an FDA-registered male incontinence device. The product launch is planned for Q3 2024. The device is approved for Medicare reimbursement and supported by several private insurers.
The global male urinary incontinence market, valued at $6.37 billion in 2022, is projected to grow at a CAGR of 5.87% from 2023 to 2030. This growth is driven by increasing incontinence prevalence, an aging population, and technological advancements. The GeeWhiz catheter aims to provide enhanced comfort, security, and ease of use for men with urinary incontinence and bladder control issues.
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the launch of a direct-to-consumer DNA test for opioid addiction predisposition through its 40% owned Laboratory Services MSO. The DNA4Addiction test analyzes 15 genetic markers linked to opioid dependence, categorizing individuals into risk levels. This non-invasive, at-home test comes amid the ongoing opioid crisis, with opioids involved in over 75% of nearly 107,000 drug overdose deaths in 2022.
The test aims to provide insights for proactive health management, though it is not a diagnosis. It examines factors such as neurotransmitter activity and substance sensitivity. Dr. David Jin, CEO of Avalon, emphasized the importance of recognizing genetic predisposition for early intervention. Bob Forrest, Brand Ambassador for DNA4Addiction, highlighted its potential in guiding lifestyle changes and preventing addiction, especially for parents concerned about their children's risks.
FAQ
What is the current stock price of Avalon Globocare (ALBT)?
What is the market cap of Avalon Globocare (ALBT)?
